Xenon Pharmaceuticals Inc. (XENE) insider trading

By person

24 insiders · 219 transactions

1.6×

Ian Mortimer holds only 1.6 times base salary in stock. $1.28M of shares against $786.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Ian Mortimer last reported holding, valued at $37.38, the price Common Shares was last bought or sold at on the open market here, on 30 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Ian Mortimer

President & CEO

$1.16M (3)

$24.82M (25) scheduled

−$23.66M

78,523

0.0811%

$2.94M

+300.6%

Simon N. Pimstone

Director

$17.40K (1)

$14.96M (34)

−$14.95M

6,000

0.0062%

$224.28K

−97.2%

James R. Empfield

EVP, Drug Discovery

$24.82K (1)

$3.78M (5) scheduled

−$3.75M

10,000

0.0103%

$373.80K

—

Sherrington Robin

EVP, Strategy & Innovation

—

$3.61M (11) scheduled

−$3.61M

8,398

0.0087%

$313.92K

+108.8%

Bvf Partners L P/Il entity

10% owner

$2.05M (28)

—

+$2.05M

59,464

0.0614%

$2.22M

−96.9%

Sherry Aulin

Chief Financial Officer

—

$1.38M (3) scheduled

−$1.38M

0.0000%

$0.00

—

Steven Gannon

Director

$42.27K (1)

$1.24M (6)

−$1.20M

1,870

0.0019%

$69.90K

—

Gary Patou

Director

$35.84K (2)

$1.17M (9) scheduled

−$1.13M

29,798

0.0308%

$1.11M

+647.6%

Dawn Svoronos

Director

$140.77K (1)

$967.50K (1)

−$826.73K

31,373

0.0324%

$1.17M

—

Christopher John Kenney

Chief Medical Officer

$20.17K (1)

$694.76K (5) scheduled

−$674.60K

<0.0001%

$74.76

+100.0%

Frank A Holler

Director

—

$649.32K (7)

−$649.32K

143,653

0.1483%

$5.37M

−1.5%

Thomas Patrick Kelly

Chief Financial Officer

$559.74K (1)

—

+$559.74K

22,500

0.0232%

$841.05K

—

Andrea DiFabio

Chief Legal Officer

—

$230.81K (2) scheduled

−$230.81K

7,301

0.0075%

$272.91K

—

Seggern Christopher Von

Chief Commercial Officer

$97.60K (1)

—

+$97.60K

4,000

0.0041%

$149.52K

—

Elizabeth A. Garofalo

Director

—

$95.58K (1) scheduled

−$95.58K

2,645

0.0027%

$98.87K

—

Mohammad Azab

Director

$81.14K (5)

$214.18 (1)

+$80.93K

74,225

0.0766%

$2.77M

+1,403%

Gillian Cannon

Director

—

$63.24K (1) scheduled

−$63.24K

1,455

0.0015%

$54.39K

—

Michael R Hayden

Director

$41.25K (1)

—

+$41.25K

208,282

0.2151%

$7.79M

+169.4%

Richard H Scheller

Director

$19.95K (1)

—

+$19.95K

7,000

0.0072%

$261.66K

—

Raymond Winquist

Head, Translational Research

$3.00K (1)

—

+$3.00K

1,000

0.0010%

$37.38K

—

Michael M Tarnow

Director

—

77,942

0.0805%

$2.91M

+41.3%

Charles J. Cohen

VP, Biology

—

6,550

0.0068%

$244.84K

—

Patrick Machado

Director

—

2,645

0.0027%

$98.87K

—

Justin D. Gover

Director

—

2,645

0.0027%

$98.87K

—

Xenon Pharmaceuticals Inc.

What the insiders did Net selling

By person